11月28日，华熙生物盘中下跌2.01%，截至09:54，报46.79元/股，成交5361.81万元，换手率0.24%，总 市值225.38亿元。 资金流向方面，主力资金净流出220.33万元，特大单买入216.98万元，占比4.05%，卖出397.92万元，占 比7.42%；大单买入943.10万元，占比17.59%，卖出982.50万元，占比18.32%。 华熙生物今年以来股价跌8.13%，近5个交易日跌4.26%，近20日跌13.34%，近60日跌19.02%。 资料显示，华熙生物科技股份有限公司位于山东省济南市高新技术开发区天辰大街678号，成立日期 2000年1月3日，上市日期2019年11月6日，公司主营业务涉及微生物发酵和交联两大技术平台,开发有助 于人类生命健康的生物活性材料,建立了从原料到医疗终端产品、功能性护肤品及功能性食品的全产业 链业务体系,服务于全球的医药、化妆品、食品制造企业、医疗机构及终端用户。主营业务收入构成 为：皮肤科学创新转化业务40.34%，医疗终端产品29.76%，原料产品27.70%，其他2.17%，其他(补 充)0.03%。 截至11月20日，华熙生物股东户数3.0 ...

Core Viewpoint - Huaxi Biological experienced a stock price decline of 2.00% on September 23, with a current price of 54.34 CNY per share and a total market capitalization of 26.174 billion CNY [1] Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company operates in the fields of microbial fermentation and cross-linking technology, developing bioactive materials that contribute to human health [1] - The company has established a full industry chain business system, serving global pharmaceutical, cosmetic, food manufacturing enterprises, medical institutions, and end-users [1] Business Revenue Composition - The revenue composition of Huaxi Biological is as follows: - Skin science innovation transformation business: 40.34% - Medical terminal products: 29.76% - Raw material products: 27.70% - Others: 2.17% - Other (supplement): 0.03% [1] Stock Performance - Year-to-date, Huaxi Biological's stock price has increased by 6.70%, but it has seen a decline of 7.00% over the last five trading days and 6.60% over the last twenty days [1] Financial Performance - For the first half of 2025, Huaxi Biological reported a revenue of 2.261 billion CNY, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million CNY, down 35.38% year-on-year [2] Shareholder Information - As of July 31, the number of shareholders of Huaxi Biological was 32,500, an increase of 1.78% from the previous period. The average circulating shares per person decreased by 1.75% to 14,799 shares [2] Dividend Distribution - Since its A-share listing, Huaxi Biological has distributed a total of 1.138 billion CNY in dividends, with 528 million CNY distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, major shareholders include: - Huaxia SSE Sci-Tech Innovation Board 50 ETF (588000) - 10.6429 million shares, down 244,800 shares - E Fund SSE Sci-Tech Innovation Board 50 ETF (588080) - 7.9777 million shares, up 227,800 shares - Huabao CSI Medical ETF (512170) - 6.4329 million shares, newly entered - Hong Kong Central Clearing Limited - 5.7990 million shares, up 1.3124 million shares [3]

Company Overview - Huaxi Biological Technology Co., Ltd. is located in Jinan, Shandong Province, established on January 3, 2000, and listed on November 6, 2019. The company specializes in microbial fermentation and cross-linking technology platforms, developing bioactive materials that benefit human health. It has established a full industry chain from raw materials to medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing companies, medical institutions, and end-users [2]. Financial Performance - As of July 31, the number of Huaxi Biological shareholders reached 32,500, an increase of 1.78% from the previous period. The average circulating shares per person decreased by 1.75% to 14,799 shares [2]. - For the first half of 2025, Huaxi Biological reported operating revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%. The net profit attributable to the parent company was 221 million yuan, down 35.38% year-on-year [2]. Stock Performance - Huaxi Biological's stock price has increased by 14.59% year-to-date, with a 1.81% rise over the last five trading days, a 13.65% increase over the last 20 days, and a 6.69% increase over the last 60 days [2]. - On September 1, the stock price rose by 2.03%, reaching 58.36 yuan per share, with a trading volume of 246 million yuan and a turnover rate of 0.89%. The total market capitalization stood at 28.111 billion yuan [1]. Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders included various ETFs, with notable changes in holdings. For instance, Huaxia SSE Sci-Tech Innovation Board 50 ETF held 10.6429 million shares, down 244,800 shares from the previous period. Meanwhile, the E Fund SSE Sci-Tech Innovation Board 50 ETF increased its holdings by 227,800 shares to 7.9777 million shares [3].